Rubino Antonino S, Santarpino Giuseppe, De Praetere Herbert, Kasama Keiichiro, Dalén Magnus, Sartipy Ulrik, Lahtinen Jarmo, Heikkinen Jouni, Deste Wanda, Pollari Francesco, Svenarud Peter, Meuris Bart, Fischlein Theodor, Mignosa Carmelo, Biancari Fausto
Cardiac Surgery Unit, A.O.U. Policlinico-Vittorio Emanuele, University of Catania, Catania, Italy.
Department of Cardiac Surgery, Klinikum Nürnberg, Nuremberg, Germany.
J Thorac Cardiovasc Surg. 2014 Sep;148(3):865-71; discussion 871. doi: 10.1016/j.jtcvs.2014.03.052. Epub 2014 Apr 4.
The aim of this study was to evaluate the outcome of aortic valve replacement with the sutureless Perceval S aortic valve bioprosthesis (Sorin Biomedica Cardio Srl, Saluggia, Italy).
This is a retrospective analysis of 314 patients (mean age, 77.9 ± 5.0 years, mean European System for Cardiac Operative Risk Evaluation II, 9.0% ± 7.6%) who underwent aortic valve replacement with the Perceval S valve with (94 patients) or without (220 patients) concomitant coronary artery bypass surgery at 5 European centers.
The Perceval S valve was successfully implanted in all but 1 patient (99.7%). The mean aortic crossclamping time was 43 ± 20 minutes (isolated procedure, 39 ± 15 minutes; concomitant coronary surgery, 52 ± 26 minutes). Severe paravalvular leak occurred in 2 patients (0.6%). In-hospital mortality was 3.2% (1.4% after isolated procedure and 7.4% after concomitant coronary surgery). In-hospital mortality was 2.8% and 4.0% among patients with a European System for Cardiac Operative Risk Evaluation II less than 10% and 10% or greater, respectively (P = .558). Octogenarians had slightly higher in-hospital mortality (5.2% vs 2.0%, P = .125; after isolated procedure: 2.7% vs 0.7%, P = .223; after concomitant coronary surgery: 9.5% vs 5.8%, P = .491) compared with younger patients. Full sternotomy did not increase the in-hospital mortality risk compared with ministernotomy or minithoracotomy access (1.3% vs 1.4%, when adjusted for baseline covariates: P = .921; odds ratio, 0.886; 95% confidence interval, 0.064-12.346). One-year survival was 90.5%. Freedom from valve-related mortality, stroke, endocarditis, and reoperation was 99.0%, 98.1%, 99.2%, and 98.3%, respectively.
The sutureless Perceval S valve is associated with excellent early survival in high-risk patients, particularly among those undergoing an isolated procedure. Further studies are needed to prove the durability of this bioprosthesis.
本研究旨在评估采用无缝合Perceval S主动脉瓣生物假体(意大利萨卢贾索林生物医学心脏公司)进行主动脉瓣置换术的结果。
这是一项对314例患者(平均年龄77.9±5.0岁,平均欧洲心脏手术风险评估系统II评分为9.0%±7.6%)的回顾性分析,这些患者在5个欧洲中心接受了使用Perceval S瓣膜的主动脉瓣置换术,其中94例患者同时进行了冠状动脉搭桥手术,220例患者未进行该手术。
除1例患者外(99.7%),所有患者的Perceval S瓣膜均成功植入。平均主动脉阻断时间为43±20分钟(单纯手术为39±15分钟;同期冠状动脉手术为52±26分钟)。2例患者(0.6%)发生严重瓣周漏。住院死亡率为3.2%(单纯手术后为1.4%,同期冠状动脉手术后为7.4%)。欧洲心脏手术风险评估系统II评分低于10%和10%及以上的患者住院死亡率分别为2.8%和4.0%(P = 0.558)。与年轻患者相比,80岁及以上患者的住院死亡率略高(5.2%对2.0%,P = 0.125;单纯手术后:2.7%对0.7%,P = 0.223;同期冠状动脉手术后:9.5%对5.8%,P = 0.491)。与胸骨旁小切口或胸腔镜小切口入路相比,全胸骨切开术并未增加住院死亡风险(调整基线协变量后为1.3%对1.4%:P = 0.921;比值比为0.886;95%置信区间为0.064 - 12.346)。1年生存率为90.5%。无瓣膜相关死亡、中风、心内膜炎和再次手术的比例分别为99.0%、98.1%、99.2%和98.3%。
无缝合Perceval S瓣膜在高危患者中,尤其是在接受单纯手术的患者中,具有出色的早期生存率。需要进一步研究来证实这种生物假体的耐久性。